Alison H Kohn1, Afsaneh Alavi2,3, April W Armstrong4, Folawiyo Babalola5, Amit Garg6, Alice B Gottlieb7, Lesley Grilli8, Gregor Borut Ernst Jemec9, John Latella10, Kendall Marcus11, Joseph F Merola12, Alex G Ortega-Loayza13, Daniel M Siegel14, Vibeke Strand15, Jerry K L Tan16, Lourdes M Perez-Chada17. 1. Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, USA. 2. Division of Dermatology, University of Toronto, Toronto, Ontario, Canada. 3. Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA, armstrongpublication@gmail.com. 5. Joe R. & Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. 6. Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York, USA. 7. Department of Dermatology, Icahn School of Medicine at Mt Sinai, New York, New York, USA. 8. Patient Research Partner, International Dermatology Outcome Measures (IDEOM), Cohasset, Massachusetts, USA. 9. Department of Dermatology, Zealand University Hospital, Roskilde, Denmark. 10. Patient Research Partner, International Dermatology Outcome Measures (IDEOM), Windsor, Connecticut, USA. 11. Division of Dermatology and Dental Products, Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland, USA. 12. Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA. 13. Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA. 14. Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, New York, USA. 15. Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA. 16. Faculty of Medicine, Western University, London, Ontario, Canada. 17. Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Abstract
BACKGROUND: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. SUMMARY: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. KEY MESSAGES: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting. The Author(s). Published by S. Karger AG, Basel.
BACKGROUND: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. SUMMARY: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. KEY MESSAGES: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting. The Author(s). Published by S. Karger AG, Basel.
Authors: Alice B Gottlieb; April W Armstrong; Robin Christensen; Amit Garg; Kristina Callis Duffin; Wolf-Henning Boehncke; Joseph F Merola; Dafna D Gladman; Philip J Mease; Robert A Swerlick; Cheryl F Rosen; April Abernethy Journal: J Rheumatol Date: 2014-06 Impact factor: 4.666
Authors: C A C Prinsen; L B Mokkink; L M Bouter; J Alonso; D L Patrick; H C W de Vet; C B Terwee Journal: Qual Life Res Date: 2018-02-12 Impact factor: 4.147
Authors: Kristina Callis Duffin; Joseph F Merola; Robin Christensen; John Latella; Amit Garg; Alice B Gottlieb; April W Armstrong Journal: JAMA Dermatol Date: 2018-10-01 Impact factor: 10.282
Authors: Lourdes Perez-Chada; Vanina L Taliercio; Alice Gottlieb; Marta Van Beek; Kristina Callis Duffin; Margo Reeder; Joseph F Merola; Robert A Swerlick Journal: J Am Acad Dermatol Date: 2019-09-13 Impact factor: 11.527
Authors: L Thorlacius; J R Ingram; B Villumsen; S Esmann; J S Kirby; A B Gottlieb; J F Merola; R Dellavalle; S M Nielsen; R Christensen; A Garg; G B E Jemec Journal: Br J Dermatol Date: 2018-07-05 Impact factor: 11.113